Peanut Allergy Market Summary
The Peanut Allergy Treatment Market across the seven major markets (7MM) was valued at approximately USD 533 million in 2025 and is projected to experience robust growth throughout the forecast period. The market is expected to reach nearly USD 2,464 million by 2034, registering a CAGR of 18.50%. This remarkable growth is primarily driven by the increasing prevalence of peanut allergy, growing awareness regarding food allergies, expanding diagnosis rates, and the introduction of innovative therapies designed to improve patient outcomes.
Among the seven major markets, the United States accounted for the largest Peanut Allergy Treatment Market in 2025, followed by the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The current treatment landscape is evolving rapidly with approved therapies such as PALFORZIA and XOLAIR, while a strong clinical pipeline featuring candidates including Viaskin Peanut Patch, Remibrutinib, PVX108, SLIT-Tablet, INP20, and INT301 is expected to significantly reshape the Peanut Allergy market during the forecast period.
Explore DelveInsight’s Full Coverage on the Peanut Allergy Market
Peanut Allergy Overview
Peanut Allergy is one of the most common and severe food allergies worldwide and has become increasingly prevalent over the past several decades, particularly among children. It results from an abnormal immunoglobulin E (IgE)-mediated immune response against peanut proteins, which may trigger severe allergic reactions, including life-threatening anaphylaxis.
The condition generally develops during infancy or early childhood, with symptoms frequently appearing as early as four months of age and usually within the first two years of life. Although nearly 20% of affected children naturally outgrow Peanut Allergy, the majority continue to experience persistent allergic sensitivity throughout adulthood.
Following the first exposure to peanut allergens, Th2 lymphocytes stimulate the production of IgE antibodies that bind to mast cells and basophils. Upon subsequent exposure, peanut proteins cross-link these IgE antibodies, resulting in rapid degranulation of immune cells and release of inflammatory mediators such as histamine, leukotrienes, and cytokines. This cascade produces symptoms ranging from mild itching and urticaria to severe respiratory distress and systemic anaphylaxis.
Peanut Allergy significantly affects patients’ quality of life and requires lifelong vigilance due to the risk of accidental exposure.
Peanut Allergy Diagnosis and Treatment Algorithm
Diagnosis of Peanut Allergy relies primarily on a detailed clinical history supported by appropriate diagnostic testing. The double-blind, placebo-controlled food challenge (DBPCFC) remains the gold standard for confirming food allergy.
Additional diagnostic tools include:
- Skin Prick Test (SPT)
- Serum-specific IgE testing
- Molecular allergy diagnosis
- Oral Food Challenge (OFC)
- Bead-based Epitope Assay (BBEA)
Although Skin Prick Tests and serum IgE testing provide high sensitivity, they possess relatively low specificity and therefore must always be interpreted alongside the patient’s clinical history to minimize false-positive and false-negative diagnoses.
Management of Peanut Allergy primarily focuses on strict allergen avoidance and preparedness for emergency treatment. Immediate intramuscular epinephrine remains the only definitive therapy for anaphylaxis, while antihistamines and corticosteroids are considered supportive treatments rather than substitutes for epinephrine.
Recent preventive strategies recommend the early introduction of peanut-containing foods between four and six months of age, particularly in high-risk infants, as this approach has demonstrated a significant reduction in the future development of Peanut Allergy.
Current immunotherapeutic approaches include:
- Oral Immunotherapy (OIT)
- Sublingual Immunotherapy (SLIT)
- Epicutaneous Immunotherapy (EPIT)
These approaches aim to increase tolerance to peanut allergens and reduce the likelihood of severe allergic reactions following accidental exposure.
Peanut Allergy Market Players
Peanut Allergy companies include:
- Stallergenes Greer
- Roche
- Novartis
- DBV Technologies
- Aravax
- ALK-Abello
- InnoUp Farma
- Allergy Therapeutics
- Intrommune Therapeutics
- Nestlé Health Science
- Regeneron Pharmaceuticals
- Camallergy
- Vedanta Biosciences
- Alladapt Immunotherapeutics
- COUR Pharmaceuticals
- Genentech
- And others.
Peanut Allergy Epidemiology
The epidemiology section of the Peanut Allergy Market report provides historical and forecasted patient population data across the seven major markets (7MM). The analysis includes diagnosed prevalent cases segmented by age, gender, and disease severity, along with expert insights explaining historical trends and anticipated market evolution.
Key Findings:
- In 2024, approximately 9.8 million diagnosed prevalent Peanut Allergy cases were reported across the 7MM.
- The United States accounted for the highest diagnosed prevalent patient population.
- Among the EU4 and the UK, Germany reported the highest number of Peanut Allergy cases in 2024.
- In Japan, the highest age-specific prevalence was observed among individuals aged 41–64 years, followed by patients aged 65 years and above.
- Mild and moderate Peanut Allergy cases were slightly more common than severe cases.
- Peanut Allergy was observed more frequently among females than males.
- The epidemiology of Peanut Allergy is expected to continue evolving throughout the forecast period (2025–2034), supported by increasing awareness, improved diagnosis, and greater recognition of food allergies.
Download the Peanut Allergy Market Report for In-Depth Insights on Pipeline and Forecast
Peanut Allergy Market Outlook
The Peanut Allergy Treatment Market is expected to witness substantial expansion during the forecast period owing to rising disease prevalence, increasing awareness, improved diagnosis, expanding therapeutic options, and a strong pipeline of innovative therapies.
The total Peanut Allergy Treatment Market across the 7MM was valued at approximately USD 533 million in 2025 and is projected to reach nearly USD 2,464 million by 2034, growing at a CAGR of 18.50%.
Among the seven major markets, the United States represents the largest market, while Germany accounts for the largest market among the European countries.
Current treatment relies largely on allergen avoidance, epinephrine administration, and approved therapies including PALFORZIA and XOLAIR. However, the treatment landscape is expected to undergo significant transformation with emerging therapies such as Viaskin Peanut Patch, Remibrutinib, PVX108, SLIT-Tablet, INP20, and INT301, each targeting different mechanisms of action to improve long-term disease management.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail: abhishek@delveinsight.com
